Traws Pharma closed at $0.27 on Nov 4, down 11.06%, within 0.0% of its 52-week closing low. Volume of 128.0K shares was 0.72× its 20-day average (below normal).
Split-adjusted performance: -48.3% over one month, -84.2% over six months, -88.8% over one year.
Short interest was 685.7K shares at the Oct 15 settlement (5.2% of float, 3.7 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| TRAWTraws Pharma | $0.2686 | −11.06% | −84.2% | −100.0% | — | — | $4.1M | |
| DRMADermata Therapeutics | $0.8548 | +0.72% | −32.7% | — | — | — | $4.2M | Compare |
| ONCOOnconetix | $0.6583 | +15.69% | −85.4% | −83.9% | −16748.3% | — | $3.9M | Compare |
| APUSApimeds Pharmaceuticals US | $2.92 | −1.68% | −85.0% | — | — | — | $4.4M | Compare |
| CVKDCadrenal Therapeutics | $1.06 | −6.19% | −82.8% | — | — | — | $3.8M | Compare |
| TCRTAlaunos Therapeutics | $1.80 | −3.23% | −31.6% | — | — | — | $4.6M | Compare |
| XBIOXenetic Biosciences | $2.01 | −3.37% | −36.6% | +12.0% | −140.7% | — | $4.7M | Compare |
| MDCXMedicus Pharma | $1.88 | −7.39% | −88.7% | — | — | — | $3.6M | Compare |
| AZTRAzitra | $0.8157 | −7.71% | −66.7% | — | — | — | $4.9M | Compare |
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
